|
1
|
Hundal R and Shaffer EA: Gallbladder
cancer: Epidemiology and outcome. Clin Epidemiol. 6:99–109.
2014.PubMed/NCBI
|
|
2
|
Gamboa AC and Maithel SK: The landmark
series: Gallbladder cancer. Ann Surg Oncol. 27:2846–2858. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Song X, Hu Y, Li Y, Shao R, Liu F and Liu
Y: Overview of current targeted therapy in gallbladder cancer.
Signal Transduct Target Ther. 5:2302020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Goetze TO: Gallbladder carcinoma:
Prognostic factors and therapeutic options. World J Gastroenterol.
21:12211–12217. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kuna RS and Field SJ: GOLPH3: A Golgi
phosphatidylinositol(4)phosphate effector that directs vesicle
trafficking and drives cancer. J Lipid Res. 60:269–275. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhou X, Xue P, Yang M, Shi H, Lu D, Wang
Z, Shi Q, Hu J, Xie S, Zhan W and Yu R: Protein kinase D2 promotes
the proliferation of glioma cells by regulating Golgi
phosphoprotein 3. Cancer Lett. 355:121–129. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sechi S, Frappaolo A, Karimpour-Ghahnavieh
A, Piergentili R and Giansanti MG: Oncogenic roles of GOLPH3 in the
physiopathology of cancer. Int J Mol Sci. 21:9332020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Farber-Katz SE, Dippold HC, Buschman MD,
Peterman MC, Xing M, Noakes CJ, Tat J, Ng MM, Rahajeng J, Cowan DM,
et al: DNA damage triggers Golgi dispersal via DNA-PK and GOLPH3.
Cell. 156:413–427. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Buschman MD, Xing M and Field SJ: The
GOLPH3 pathway regulates Golgi shape and function and is activated
by DNA damage. Front Neurosci. 9:3622015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bergeron JJM, Au CE, Thomas DY and Hermo
L: Proteomics identifies Golgi phosphoprotein 3 (GOLPH3) with a
link between Golgi structure, cancer, DNA damage and protection
from cell death. Mol Cell Proteomics. 16:2048–2054. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tang S, Pan H, Wei W, Yang H, Liu J and
Yang R: GOLPH3: A novel biomarker that correlates with poor
survival and resistance to chemotherapy in breast cancer.
Oncotarget. 8:105155–105169. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu H, Wang X, Feng B, Tang L, Li W, Zheng
X, Liu Y, Peng Y, Zheng G and He Q: Golgi phosphoprotein 3 (GOLPH3)
promotes hepatocellular carcinoma progression by activating mTOR
signaling pathway. BMC Cancer. 18:6612018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu J, Wei H, Lai L, Wang Y, Han X and
Zhang Z: Golgi phosphoprotein-3 promotes invasiveness of gastric
cancer cells through the mTOR signalling pathway. Clin Invest Med.
42:E38–E47. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhao C, Zhang J, Ma L, Wu H, Zhang H, Su
J, Geng B, Yao Q and Zheng J: GOLPH3 promotes angiogenesis of lung
adenocarcinoma by regulating the Wnt/β-catenin signaling pathway.
Onco Targets Ther. 13:6265–6277. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang Q, Zhuang J, Deng Y, Yang L, Cao W,
Chen W, Lin T, Lv X, Yu H, Xue Y and Guo H: miR34a/GOLPH3 axis
abrogates urothelial bladder cancer chemoresistance via reduced
cancer stemness. Theranostics. 7:4777–4790. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yu T, An Q, Cao XL, Yang H, Cui J, Li ZJ
and Xiao G: GOLPH3 inhibition reverses oxaliplatin resistance of
colon cancer cells via suppression of PI3K/AKT/mTOR pathway. Life
Sci. 260:1182942020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zeng Z, Lin H, Zhao X, Liu G, Wang X, Xu
R, Chen K, Li J and Song L: Overexpression of GOLPH3 promotes
proliferation and tumorigenicity in breast cancer via suppression
of the FOXO1 transcription factor. Clin Cancer Res. 18:4059–4069.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lim Y and Kumar S: A single cut to
pyroptosis. Oncotarget. 6:36926–36927. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Islam MT, Bardaweel SK, Mubarak MS, Koch
W, Gaweł-Beben K, Antosiewicz B and Sharifi-Rad J: Immunomodulatory
effects of diterpenes and their derivatives through NLRP3
inflammasome pathway: A review. Front Immunol. 11:5721362020.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Latz E, Xiao TS and Stutz A: Activation
and regulation of the Inflammasomes. Nat Rev Immunol. 13:397–411.
2013. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen J and Chen ZJ: PtdIns4P on dispersed
trans-Golgi network mediates NLRP3 inflammasome activation. Nature.
564:71–76. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Feng YS, Tan ZX, Wu LY, Dong F and Zhang
F: The involvement of NLRP3 inflammasome in the treatment of
Alzheimer's disease. Ageing Res Rev. 64:1011922020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lu F, Zhao Y, Pang Y, Ji M, Sun Y, Wang H,
Zou J, Wang Y, Li G, Sun T, et al: NLRP3 inflammasome upregulates
PD-L1 expression and contriwhilees to immune suppression in
lymphoma. Cancer Lett. 497:178–189. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tezcan G, Garanina EE, Zhuravleva MN,
Hamza S, Rizvanov AA and Khaiboullina SF: Rab GTPase mediating
regulation of NALP3 in colorectal cancer. Molecules. 25:48342020.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang Y, Kong H, Zeng X, Liu W, Wang Z, Yan
X, Wang H and Xie W: Activation of NLRP3 inflammasome enhances the
proliferation and migration of A549 lung cancer cells. Oncol Rep.
35:2053–2064. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen Z, Liu Q, Zhu Z, Xiang F, Zhang M, Wu
R and Kang X: Ursolic acid protects against proliferation and
inflammatory response in LPS-Treated gastric tumour model and cells
by inhibiting NLRP3 inflammasome activation. Cancer Manag Res.
12:8413–8424. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen Z, He M, Chen J, Li C and Zhang Q:
Long non-coding RNA SNHG7 inhibits NLRP3-dependent pyroptosis by
targeting the miR-34a/SIRT1 axis in liver cancer. Oncol Lett.
20:893–901. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Guo R, Qin Y, Shi P, Xie J, Chou M and
Chen Y: IL-1β promotes proliferation and migration of gallbladder
cancer cells via Twist activation. Oncol Lett. 12:4749–4755. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Dippold HC, Ng MM, Farber-Katz SE, Lee SK,
Kerr ML, Peterman MC, Sim R, Wiharto PA, Galbraith KA, Madhavarapu
S, et al: GOLPH3 bridges phosphatidylinositol-4-phosphate and
actomyosin to stretch and shape the Golgi to promote budding. Cell.
139:337–351. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li X, Zhang X, Pan Y, Shi G, Ren J, Fan H,
Dou H and Hou Y: mTOR regulates NLRP3 inflammasome activation via
reactive oxygen species in murine lupus. Acta Biochim Biophys Sin
(Shanghai). 50:888–896. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang Z, Meszaros G, He WT, Xu Y, de
Fatima Magliarelli H, Mailly L, Mihlan M, Liu Y, Puig Gámez M,
Goginashvili A, et al: Protein kinase D at the Golgi controls NLRP3
inflammasome activation. J Exp Med. 214:2671–2693. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Friedrichs K, Gluba S, Eidtmann H and
Jonat W: Overexpression of p53 and prognosis in breast cancer.
Cancer. 72:3641–3647. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lamartina L, Grani G, Arvat E, Nervo A,
Zatelli MC, Rossi R, Puxeddu E, Morelli S, Torlontano M, Massa M,
et al: 8th edition of the AJCC/TNM staging system of thyroid
cancer: What to expect (ITCO#2). Endocr Relat Cancer. 25:L7–L11.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hui AM, Shi YZ, Li X, Sun L, Guido T,
Takayama T and Makuuchi M: Proliferative marker Ki-67 in
gallbladder carcinomas: High expression level predicts early
recurrence after surgical resection. Cancer Lett. 176:191–198.
2002. View Article : Google Scholar : PubMed/NCBI
|
